Last reviewed · How we verify
NCT04598724
Addressing Barriers to Palliative Care Use in Bladder Cancer
trial testing Surveys in Muscle-Invasive Bladder Carcinoma in 54 participants. Completed in 10 May 2021.
10 May 2021
Quick facts
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 22 December 2020 |
| Primary completion | 10 May 2021 |
| Estimated completion | 10 May 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Surveys
Conditions studied
- Muscle-Invasive Bladder Carcinoma — all drugs for Muscle-Invasive Bladder Carcinoma →
- Bladder Cancer Stage II — all drugs for Bladder Cancer Stage II →
- Bladder Cancer Stage III — all drugs for Bladder Cancer Stage III →
- Bladder Cancer Stage IV — all drugs for Bladder Cancer Stage IV →
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Who can join
18 and older, any sex, with Muscle-Invasive Bladder Carcinoma or Bladder Cancer Stage II. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators plan to establish an in-depth understanding of knowledge and beliefs about palliative care in advanced Bladder Cancer patients and their caregivers, and to identify factors associated with positive and negative experiences with palliative care services among those who have received them.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04598724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surveys
Trials testing the same drug.
- NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
- NCT07137468 — Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk · recruiting
- NCT07010081 — Using Digital Health in a Postoperative Setting After Major Surgery: Survey Study · NA · recruiting
- NCT06962995 — Multi-Cancer Detection Observational Cohort Study · recruiting
- NCT06960499 — Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy · not yet recruiting
Other recruiting trials for Muscle-Invasive Bladder Carcinoma
Currently open trials in the same condition.
- NCT07339761 — Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study · NA · recruiting
- NCT07234968 — Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy · NA · recruiting
- NCT06537154 — NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment · Phase 2, PHASE3 · recruiting
- NCT06470282 — Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer · Phase 1, PHASE2 · recruiting
- NCT06529822 — Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease · Phase 1 · recruiting
Other H. Lee Moffitt Cancer Center and Research Institute trials
Trials by the same sponsor.
- NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
- NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
- NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
- NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
- NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04598724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
- Last refreshed: 3 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing